These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 7651437)

  • 41. Oncogenic forms of p53 inhibit p53-regulated gene expression.
    Kern SE; Pietenpol JA; Thiagalingam S; Seymour A; Kinzler KW; Vogelstein B
    Science; 1992 May; 256(5058):827-30. PubMed ID: 1589764
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transactivation ability of p53 transcriptional activation domain is directly related to the binding affinity to TATA-binding protein.
    Chang J; Kim DH; Lee SW; Choi KY; Sung YC
    J Biol Chem; 1995 Oct; 270(42):25014-9. PubMed ID: 7559631
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interaction of human polyomavirus BK with the tumor-suppressor protein p53.
    Shivakumar CV; Das GC
    Oncogene; 1996 Jul; 13(2):323-32. PubMed ID: 8710371
    [TBL] [Abstract][Full Text] [Related]  

  • 44. DNA binding and bending by the transcription factors GAL4(62*) and GAL4(149*).
    Rodgers KK; Coleman JE
    Protein Sci; 1994 Apr; 3(4):608-19. PubMed ID: 8003979
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A proliferative p53-responsive element mediates tumor necrosis factor alpha induction of the human immunodeficiency virus type 1 long terminal repeat.
    Gualberto A; Hixon ML; Finco TS; Perkins ND; Nabel GJ; Baldwin AS
    Mol Cell Biol; 1995 Jun; 15(6):3450-9. PubMed ID: 7760842
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Two cellular proteins that bind to wild-type but not mutant p53.
    Iwabuchi K; Bartel PL; Li B; Marraccino R; Fields S
    Proc Natl Acad Sci U S A; 1994 Jun; 91(13):6098-102. PubMed ID: 8016121
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structure and functionality of a designed p53 dimer.
    Davison TS; Nie X; Ma W; Lin Y; Kay C; Benchimol S; Arrowsmith CH
    J Mol Biol; 2001 Mar; 307(2):605-17. PubMed ID: 11254385
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mammalian p53 can function as a transcription factor in yeast.
    Schärer E; Iggo R
    Nucleic Acids Res; 1992 Apr; 20(7):1539-45. PubMed ID: 1579447
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Distance constraints and stereospecific alignment requirements characteristic of p53 DNA-binding consensus sequence homologies.
    Cook JL; Ré RN; Giardina JF; Fontenot FE; Cheng DY; Alam J
    Oncogene; 1995 Aug; 11(4):723-33. PubMed ID: 7651736
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The requirement of the carboxyl terminus of p53 for DNA binding and transcriptional activation depends on the specific p53 binding DNA element.
    Zhang W; Guo XY; Deisseroth AB
    Oncogene; 1994 Sep; 9(9):2513-21. PubMed ID: 8058314
    [TBL] [Abstract][Full Text] [Related]  

  • 51. DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53.
    Kim E; Albrechtsen N; Deppert W
    Oncogene; 1997 Aug; 15(7):857-69. PubMed ID: 9266973
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain.
    Selivanova G; Ryabchenko L; Jansson E; Iotsova V; Wiman KG
    Mol Cell Biol; 1999 May; 19(5):3395-402. PubMed ID: 10207063
    [TBL] [Abstract][Full Text] [Related]  

  • 53. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
    Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
    Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A genetic approach to mapping the p53 binding site in the MDM2 protein.
    Freedman DA; Epstein CB; Roth JC; Levine AJ
    Mol Med; 1997 Apr; 3(4):248-59. PubMed ID: 9131587
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA.
    Balagurumoorthy P; Sakamoto H; Lewis MS; Zambrano N; Clore GM; Gronenborn AM; Appella E; Harrington RE
    Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8591-5. PubMed ID: 7567980
    [TBL] [Abstract][Full Text] [Related]  

  • 56. p53 binds to the TATA-binding protein-TATA complex.
    Martin DW; Muñoz RM; Subler MA; Deb S
    J Biol Chem; 1993 Jun; 268(18):13062-7. PubMed ID: 8514746
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A carboxyl-terminal extension of the zinc finger domain contributes to the specificity and polarity of peroxisome proliferator-activated receptor DNA binding.
    Hsu MH; Palmer CN; Song W; Griffin KJ; Johnson EF
    J Biol Chem; 1998 Oct; 273(43):27988-97. PubMed ID: 9774413
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding.
    Waterman JL; Shenk JL; Halazonetis TD
    EMBO J; 1995 Feb; 14(3):512-9. PubMed ID: 7859740
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relationship between P-box amino acid sequence and DNA binding specificity of the thyroid hormone receptor. The effects of half-site sequence in everted repeats.
    Nelson CC; Hendy SC; Romaniuk PJ
    J Biol Chem; 1995 Jul; 270(28):16981-7. PubMed ID: 7622518
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA.
    Veprintsev DB; Fersht AR
    Nucleic Acids Res; 2008 Mar; 36(5):1589-98. PubMed ID: 18234719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.